Olanib 150 (Olaparib 150mg) box of 112 tablets
Olanib 150 (Olaparib 150mg) box of 112 tablets
Blog Article
Olanib 150mg is a drug made from the main ingredient Olaparib, which is used in the treatment of cancer. Olaparib is used in the following cases: ovarian cancer, breast cancer, fallopian tube cancer,... The drug is not recommended for use in pregnant women and women who are breastfeeding.
Ingredients of Olanib 150mg
Olaparib: 150mg.
Excipients just enough 1 tablet.
Dosage form
Tablets.
What is cancer?
Cancer is a general term used to Olanib 150 mg (Olaparib) describe a group of diseases that reflect changes in cell reproduction, growth, and function. Normal cells become abnormal and grow uncontrollably, invading nearby tissues (local invasion) or distant tissues (metastasis) through the lymphatic system or blood vessels. Metastasis is the main cause of cancer death.
Uses - Indications of Olanib 150mg
Olanib 150mg is indicated for treatment in the following cases:
Treatment of advanced or stage III breast cancer that has a BRCA mutation (a type of genetic mutation that causes cancer).
Treatment of advanced or recurrent ovarian cancer in patients with BRCA mutations.
Treatment of advanced or recurrent pancreatic cancer with BRCA mutations.
Treatment of advanced prostate cancer with BRCA or ATM mutations
How to use - dosage of Olanib 150mg
How to use: Oral medication.
Dosage: The recommended dose is 300 mg, taken twice daily, equivalent to a total daily dose of 600 mg.
Contraindications of Olanib 150mg
People who are sensitive to any ingredient of the drug.
Notes when using Olanib 150mg
Myelodysplastic syndrome/acute myeloid leukemia may occur with Olanib. Do not initiate therapy until the patient has recovered from hematologic toxicity from previous chemotherapy. Monitor complete blood counts for cytopenias at baseline and monthly thereafter for clinically significant changes during treatment.
If the patient develops new or worsening respiratory symptoms such as dyspnea, cough, and fever, or develops radiographic abnormalities, interrupt Olanib treatment and promptly evaluate the source of the symptoms. If pneumonitis is confirmed, discontinue Olanib treatment and treat the patient for pneumonitis.
Venous thromboembolic events, including pulmonary embolism, occurred in 7% of patients with metastatic castration-resistant prostate cancer treated with olapanib plus androgen deprivation therapy. Monitor patients for signs and symptoms of venous thromboembolism and pulmonary embolism and treat as medically appropriate, which may include long-term anticoagulation as clinically indicated.
Use for pregnant or lactating women
Not recommended for use by pregnant or lactating women.
Use for drivers and machine operators
Consult your doctor.
Side effects of Olanib 150mg
Some side effects that may occur when using Olanib 150mg: fever, weakness, dizziness, fatigue, easy bruising, unusual bleeding, pale skin, cold hands and feet, cough, shortness of breath,...
Interact
Clinical studies of Olapanib with other myelosuppressive antineoplastic agents, including DNA-damaging agents, have shown the potential for increased and prolonged myelosuppressive toxicity.
Coadministration of CYP3A inhibitors may increase olaparib concentrations, which may increase the risk of adverse reactions. Avoid coadministration with strong or moderate CYP3A inhibitors. If coadministration with strong or moderate inhibitors is required, reduce the dose of Olanib.
Concomitant use with strong or moderate CYP3A inducers reduces olaparib exposure, which may reduce Olanib efficacy. Avoid coadministration with strong or moderate CYP3A inducers.
Phone: +8801933042721
Email: iebpharma108@gmail.com
Sector 3, Road 8, Uttara-1230 Dhaka, Bangladesh
website: https://iebpharma.com